Trilaciclib is a CDK4/6 Inhibitor for Kinds of Cancer Research
CDK4/6 is a Ser/Thr protein kinase that is active only in the G1-S phase. It is controlled by the regulatory subunit D-type cyclin and the CDK inhibitor p16INK4a; involved in the…
CDK4/6 is a Ser/Thr protein kinase that is active only in the G1-S phase. It is controlled by the regulatory subunit D-type cyclin and the CDK inhibitor p16INK4a; involved in the…
Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia) is a rare subtype of leukemia characterized by the abnormal formation of the Philadelphia chromosome, which occurs when pieces of chromosomes 9 and…
CDKs (Cyclin-dependent kinases) are the families of protein kinases first discovered for their role in regulating the cell cycle. By definition, a CDK binds a regulatory protein called a cyclin.…
The cell cycle is a highly conserved process. Additionally, this process must maintain genomic integrity and replicative capacity for proper cell maintenance and proliferation. The cell cycle consists of four…
The chimeric proteolytic enzyme (PROTAC) is a heterobifunctional small molecule. Specifically, it is composed of two active domains and an adaptor that can remove specific proteins that are not needed.…
CDK6 plays a significant role in cell cycle entrance. However, overexpression of CDK6 correlates to CDK4/6 inhibitor resistance in breast cancer cell lines and patient samples. Moreover, point mutation of…
A study from Matthias Brand reported a novel phthalimide-based degrader BSJ-03-123. This compound exploits protein-interface determinants to achieve proteome-wide selectivity for the degradation of cyclin-dependent kinase 6 (CDK6). Notably, CDK6…